trial
as of 2026-07-01Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
NCTId NCT05648591
at a glance
Phase 4 · Recruiting
Enrollment 100 (estimated)
Sponsored by Vanda Pharmaceuticals
Primary completion 2026-03-31
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Recruiting
Enrollment
100 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2023-05-24
Primary completion
2026-03-31
Eligibility
ALL · 12 Years · 17 Years
Interventions & indications
Drugs
Indications
Sponsors
Vanda PharmaceuticalsLead Sponsor
Sites
9 total
Little Rock, United StatesDenver, United StatesAtlanta, United StatesAtlanta, United StatesDecatur, United StatesCincinnati, United StatesGarfield Heights, United StatesWestlake, United StatesEverett, United States
Facts & assertions
4 sourced
Enrollment
100
Phase
PHASE4
Primary Completion Date
2026-03-31
Status
RECRUITING
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication